Need help finding what you are looking for?
Contact Us
PUBLISHER: DelveInsight | PRODUCT CODE: 2082661
PUBLISHER: DelveInsight | PRODUCT CODE: 2082661
Low-grade glioma- Epidemiology Forecast-2036
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Low Grade Glioma (LGG) Insights and Trends
- Low-grade gliomas (LGGs) are a diverse group of primary brain tumors that often occur in young, otherwise healthy patients and are characterized by an indolent, slow-growing course with longer survival compared to high-grade gliomas. Given their favorable prognosis and prolonged survival, treatment decisions must carefully balance benefits against potential treatment-related risks.
- Isocitrate dehydrogenase 1 (IDH1) and Isocitrate dehydrogenase 2 (IDH2) are the most frequently mutated genes in LGG, occurring in over 70% of cases. BRAF V600E mutations are less common but are seen in pilocytic astrocytoma and several non-pilocytic pediatric low-grade gliomas, including ganglioglioma, desmoplastic infantile ganglioglioma, and about two-thirds of pleomorphic xanthoastrocytomas.
- LGG are tumors categorized as Grades 1 or 2, because they are not very aggressive, are less likely to spread, and are slow-growing which makes them more treatable.
- The WHO classification of LGGs heavily weighs molecular mutations classifying primary brain tumors with particular importance assigned to IDH mutation, 1p/19q co-deletion, ATRX mutation, TERT mutations, and MGMT methylation. But due to the hefty cost of biomarker testing, it is possible that many patients do not have routine IDH and MGMT testing done.
- According to the secondary search, the incidence of Grade 2 astrocytoma is 0.44 per 100,000 persons, and that of Grade 3 is 0.39 per 100,000 persons. Oligodendroglioma is less common, with an incidence of 0.23 per 100,000 persons for Grade 2 and 0.11 per 100,000 persons for Grade 3 in the United States.
- Pediatric LGG is a type of tumor that affects the brain and spinal cord. LGG is the most common central nervous system (CNS) tumor in children, accounting for approximately 30% of all childhood CNS tumors.
Low Grade Glioma (LGG) Epidemiology Forecast in the 7MM
- 2025 LGG Incident Cases: ~9,300
- LGG Growth Rate (2026-2036): ~0.9% CAGR
DelveInsight's 'Low Grade Glioma (LGG) - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the LGG, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Low Grade Glioma (LGG) Understanding and Diagnosis Algorithm
Low Grade Glioma (LGG) Overview and Diagnosis
LGG is a group of slow-growing primary brain tumors classified as WHO Grade II that typically affect younger individuals, often in the prime of life. These tumors are associated with a relatively favorable prognosis compared to high-grade gliomas and are characterized by key molecular alterations, particularly IDH1/IDH2 mutations and sometimes BRAF mutations. Despite their indolent nature, LGGs are heterogeneous and can progress or recur over time, leading to variable clinical outcomes.
Low Grade Glioma (LGG) Diagnosis
Diagnosis of LGG involves a combination of imaging, histopathology, and molecular testing. MRI is the preferred modality, where LGGs typically appear T1 hypointense and T2/FLAIR hyperintense, with minimal or patchy contrast enhancement. CT scans may show low-density lesions with occasional calcifications, especially in oligodendrogliomas. While advanced imaging techniques like MRS and PET can support evaluation, histopathological examination remains the gold standard for diagnosis and grading. Molecular markers such as IDH mutation and 1p/19q codeletion are essential for accurate classification.
Low Grade Glioma (LGG) Epidemiology
Key Findings from Low Grade Glioma (LGG) Epidemiological Analysis and Forecast
- According to DelveInsight's estimates, the total incident population of LGG in the United States was ~3,800 in 2025 with a growing at a CAGR in the study period.
- In 2025, the distribution of low-grade glioma (LGG) cases in the United States shows a higher burden in Grade II tumors compared to Grade I tumors, indicating that Grade II LGGs constitute the majority of cases.
- In the United States, diffuse astrocytoma (~35%) represents the highest proportion of low-grade glioma cases, followed closely by pilocytic astrocytoma (~30%), indicating these as the dominant histopathological subtypes within LGG.
- In LGG, the highest number of cases is observed in the <18 years age group, followed by the 18-44 years group, while the lowest cases are reported in patients aged >=75 years.
- In the United States, IDH mutations (80%) represent the predominant molecular alteration in low-grade glioma (LGG), while BRAF alterations are observed in a smaller proportion of cases.
- In LGG (Grade II) in the United States, non-enhancing tumors predominate, while enhancing tumors represent a smaller proportion of cases.
Numbers are subjected to change with report updation, clinical information updates etc..
Scope of the Report:
- The report covers a segment of an executive summary, a descriptive overview of LGG, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Low Grade Glioma (LGG) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-year Forecast
- Patient Burden Trends (by geography)
FAQs:
- What are the disease risks, burdens, and unmet needs of LGG? What will be the growth opportunities across the 7MM concerning the patient population with LGG?
- What is the historical and forecasted LGG patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy:
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Product Code: DIEI1726
Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Low Grade Glioma (LGG) Epidemiology Overview at a Glance
- 4.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
- 4.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
4. Epidemiology Forecast Methodology of Low Grade Glioma (LGG)
5. Disease Background and Overview of Low Grade Glioma (LGG)
- 5.1. Introduction
- 5.2. Types
- 5.3. Symptoms
- 5.4. Causes
- 5.5. Pathophysiology
- 5.6. Diagnosis
6. Epidemiology and Patient Population of Low Grade Glioma (LGG)
- 6.1. Key Findings
- 6.2. Assumptions and Rationale
- 6.3. Total Incident Population of Low-grade Glioma in the 7MM
- 6.4. The United States
- 6.4.1. Total Incident Population of Glioma in the United States
- 6.4.2. Total Incident Population of Low-grade Glioma in the United States
- 6.4.3. Grade-specific Incident Cases of Low-grade Glioma in the United States
- 6.4.4. Age-specific Incident Cases of Low-grade Glioma in the United States
- 6.4.5. Type-specific Incident Cases of Low-grade Glioma in the United States
- 6.4.6. Low-grade Glioma Cases Based on Molecular Alterations in the United States
- 6.4.7. Enhancing and Non-enhancing Grade II Glioma Cases in the United States
- 6.5. EU4 and the UK
- 6.5.1. Total Incident Population of Glioma in EU4 and the UK
- 6.5.2. Total Incident Population of Low-grade Glioma in EU4 and the UK
- 6.5.3. Grade-specific Incident Cases of Low-grade Glioma in EU4 and the UK
- 6.5.4. Age-specific Incident Cases of Low-grade Glioma in EU4 and the UK
- 6.5.5. Type-specific Diagnosed Prevalent Cases of LGG in EU4 and the UK
- 6.5.6. Low-grade Glioma Cases Based on Molecular Alterations in EU4 and the UK
- 6.5.7. Enhancing and Non-enhancing Grade II Glioma Cases in EU4 and the UK
- 6.7. Japan
- 6.7.1. Total Incident Population of Glioma in Japan
- 6.7.2. Total Incident Population of Low-grade Glioma in Japan
- 6.7.3. Grade-specific Incident Cases of Low-grade Glioma in Japan
- 6.7.4. Age-specific Incident Cases of Low-grade Glioma in Japan
- 6.7.5. Type-specific Diagnosed Prevalent Cases of LGG in Japan
- 6.7.6. Low-grade Glioma Cases Based on Molecular Alterations in Japan
- 6.7.7. Enhancing and Non-enhancing Grade II Glioma Cases in Japan
7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
Product Code: DIEI1726
List of Tables
- Table 1: Summary of Low Grade Glioma Market, and Epidemiology (2022-2036)
- Table 2: Adult Glioma
- Table 3: Adult Glioma
- Table 4: Adult Glioma
- Table 5: Indication and Timing for RT
- Table 6: Optimal Dose of RT and Target Volume Based on Risk Stratification
- Table 7: Key treatment Recommendations for Adult Patients With Common Grade 2 Diffuse Glioma
- Table 8: Total Incident Population of Low-grade Glioma in the 7MM (2022-2036)
- Table 9: Total Incident Population of Primary Brain Cancer in the US (2022-2036)
- Table 10: Total Incident Population of Low-grade Glioma in the US (2022-2036)
- Table 11: Grade-specific Cases of Low-grade Glioma in the US (2022-2036)
- Table 12: Age-specific Cases of Low-grade Glioma in the US (2022-2036)
- Table 13: Type-specific Cases of Low-grade Glioma in the US (2022-2036)
- Table 14: Low-grade Glioma Cases Based on Molecular Alterations in the US (2022-2036)
- Table 15: Enhancing and Non-enhancing Low-grade Glioma Cases in the US (2022-2036)
- Table 16: Total Incident Population of Primary Brain Cancer in EU5 (2022-2036)
- Table 17: Total Incident Population of Low-grade Glioma in EU5 (2022-2036)
- Table 18: Grade-specific Cases of Low-grade Glioma in EU5 (2022-2036)
- Table 19: Age-specific Cases of Low-grade Glioma in EU5 (2022-2036)
- Table 20: Age-specific Cases of Low-grade Glioma in EU5 (2022-2036)
- Table 21: Low-grade Glioma Cases Based on Molecular Alterations in EU5 (2022-2036)
- Table 22: Enhancing and Non-enhancing Low-grade Glioma cases in EU5 (2022-2036)
- Table 23: Total Incident Population of Primary Brain Cancer Japan (2022-2036)
- Table 24: Total Incident Population of Low-grade Glioma in Japan (2022-2036)
- Table 25: Grade-specific Cases of Low-grade Glioma in Japan (2022-2036)
- Table 26: Age-specific Cases of Low-grade Glioma in Japan (2022-2036)
- Table 27: Type-specific Cases of Low-grade Glioma in Japan (2022-2036)
- Table 28: Low-grade Glioma Cases Based on Molecular Alterations in Japan (2022-2036)
- Table 29: Enhancing and Non-enhancing Low-grade Glioma cases in Japan (2022-2036)
List of Figures
- Figure 1: WHO classification of Brain Cancer
- Figure 2: Global Heat Map of Brain and CNS Tumor
- Figure 3: Total Incident Population of Low-grade Glioma in the 7MM (2022-2036)
- Figure 4: Total Incident Population of Glioma in the US (2022-2036)
- Figure 5: Total Incident Population of Low-grade Glioma in the US (2022-2036)
- Figure 6: Grade-specific Cases of Low-grade Glioma in the US (2022-2036)
- Figure 7: Age-specific Cases of Low-grade Glioma in the US (2022-2036)
- Figure 8: Type-specific Cases of Low-grade Glioma in the US (2022-2036)
- Figure 9: Low-grade Glioma Cases Based on Molecular Alterations in the US (2022-2036)
- Figure 10: Enhancing and Non-enhancing Grade II Glioma cases in the US (2022-2036)
- Figure 11: Total Incident Population of Glioma in the EU-5 (2022-2036)
- Figure 12: Total Incident Population of Low-grade Glioma in the EU-5 (2022-2036)
- Figure 13: Grade-specific Cases of Low-grade Glioma in the EU-5 (2022-2036)
- Figure 14: Age-specific Cases of Low-grade Glioma in the EU-5 (2022-2036)
- Figure 15: Type-specific Cases of Low-grade Glioma in the EU-5 (2022-2036)
- Figure 16: Low-grade Glioma Cases Based on Molecular Alterations in the EU-5 (2022-2036)
- Figure 17: Enhancing and Non-enhancing Grade II Glioma cases in the EU-5 (2022-2036)
- Figure 18: Total Incident Population of Glioma in Japan (2022-2036)
- Figure 19: Total Incident Population of Low-grade Glioma in Japan (2022-2036)
- Figure 20: Grade-specific Cases of Low-grade Glioma in Japan (2022-2036)
- Figure 21: Age-specific Cases of Low-grade Glioma in Japan (2022-2036)
- Figure 22: Type-specific Cases of Low-grade Glioma in Japan (2022-2036)
- Figure 23: Low-grade Glioma Cases Based on Molecular Alterations in Japan (2022-2036)
- Figure 24: Enhancing and Non-enhancing Grade II Glioma cases in Japan (2022-2036)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.